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ABSTRACT
Objective: The objective of the study was to compare the degree of micronization of the bioflavonoid fraction (90% diosmin and 10% hesperidin) of 
different manufacturers which used for the treatment of the chronic venous insufficiency.
Methods: “Detralex®,” medicines N and D, 500 mg coated tablets each were used as studied objects. Microscopy of the tablets matrix of the 
investigational drugs was performed after spontaneous decomposition in a water solution at pH=6.8, using a modular light field microscope of the 
research class B-1000BF (Optika, Italy) with a digital camera Optikam HDMI Pro (Optika, Italy) with measuring of the size of the flavonoid fraction 
granules.
Results : About 92.8% of the granules of the “Detralex®” tablets matrix were presented by the smallest size of the granules (1–5 µ), unlike D and N, 
in which 12.9% and 10% of the same size granules were observed. Giant granule size (up to 50 μm) was discovered in D and N tablets matrix and no 
such granules size were found in the “Detralex®” tablets matrix.
Conclusion: Different degrees of micronization of the purified flavonoid fraction in the studied test samples indicate that the drugs D and N are not 
pharmaceutically equivalent to the original “Detralex®” drug and cannot be considered as copies without further research.
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INTRODUCTION
Chronic venous insufficiency (CVI) - a disease of the cardiovascular 
system manifested by venous congestion due to congenital or 
acquired defects of the venous wall (defects or functional insufficiency 
of venous valves, narrowing of the lumen, or its occlusion, etc.). 
CVI includes varicose veins, post-thrombotic syndrome, primary 
venous insufficiency, and compression syndromes. This disease 
characterized by a high prevalence of up to 42% among women 
and 18% among men [1]. Treatment should be complex and include 
compression techniques, conservative, and surgical methods. 
Bioflavonoids have a wide range of pharmacological activities [2,3] 
and among conservative methods of treatment of CVI, the use of 
diosmin and hesperidin caused by their powerful phlebotonic, anti-
inflammatory, and other pharmacological properties. However, along 
with high pharmacological activity, diosmin has some pharmaceutical 
deficiencies, namely low solubility in water [4-6], which at 20°C 
is 0.0012 g/L [7]. Due to low solubility in water, diosmin is poor 
absorbed from the gastrointestinal tract. Consequently, to increase 
both bioavailability and efficiency, diosmin is increasingly micronized 
to obtain particles with a diameter of 2 μm [4,6,8].
Micronization is achieved with air jets operating at supersonic speeds 
to create repetitive collisions between particles, resulting in an average 
particle size of <2 µ. Micronization increases the rate of dissolution of 
diosmin and improves its metabolism, which, in turn, improves the 
metabolites responsible for its pharmacological activity [4,9].
The positive effect of micronization on the pharmacological activity 
of the micronized purified flavonoid fraction (MPFF), which consists 
of 90% diosmin and 10% hesperidin, has been demonstrated both 
in preclinical and clinical pharmacological studies [4,10]. In a clinical 
study [2,7], 500 mg of MPFF in dosing twice daily for 2 months 
improved clinical symptoms and reduced venous outflow rates 
compared with 300 mg of unmodified diosmin taken 3 times a day. 
Consequently, micronization is essential for the effective absorption of 
active compounds. That is why the purpose of our study was to compare 
the degree of micronization of the bioflavonoid fraction (90% diosmin 
and 10% hesperidin) of the original drug “Detralex®” and drugs of the 
various manufacturers of Ukraine.
METHODS
This article does not contain any studies with human or animal 
subjects performed by any of the authors. The following investigational 
medicinal products containing bioflavonoids diosmin and hesperidin 
were used:
• “Detralex®,” 500 mg coated tablets (15 tablets in a blister, 4 blister 
packs), Laboratories Servier Industry, France (p. 620747);
• Medicine N, coated tablets, 500 mg, No. 60 (10 tablets in a blister, 6 
blisters in a pack), Ukraine (pp. FY160317);
• Medicine D, coated tablets, 500 mg; № 60 (10 tablets in a blister, 6 
blister packs), Ukraine (pp. 162328).
Microscopy of the tablets matrix of the investigational drugs was 
performed after spontaneous decomposition in a water solution at 
pH=6.8, which corresponds to the human intestinal contents using 
a modular light field microscope of the research class B-1000BF 
(Optika, Italy) with a digital camera Optikam HDMI Pro (Optika, Italy). 
During the study with the help of special software, measurements of 
the flavonoid fraction granules were taken and distributed according 
to the size in percentage. Measurements made with magnification of 
×400, ×600, and ×1000 in the field of view of the microscope on 10 
micropreparations.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i10.28140
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RESULTS
In the course of the study, it was found that the size of the granules of 
the bioflavonoid fraction in the investigated drugs was from 1 to 50 µ, 
while in the drug “Detralex®,” most of the granules had a size of 1–5 µ 
(93% of the total number of granules), preparations D and N - 5–10 µ 
(43% and 69%, respectively) (Table 1).
The analysis of the micropreparations of the tablet matrix of drug 
“Detralex®” showed that it was formed by MPFF with a predominant 
size not exceeding 5 µ (Fig. 1). The diameter of most granules forming 
the background of micropreparations was within 2 μm (Figs. 2-5). In 
some micropreparations, granules of a flavonoid fraction which size 
was closer to 10 µ were found, but in rare cases (Figs. 1 and 2). At the 
same time, these elements were complex conglomerates of smaller 
particles of flavonoids. Unique elements that were >10 μm have not 
been observed in any of the micropreparations of the tablet matrix of 
“Detralex®” (Figs. 1-3 and 5). However, in some cases, complex granules 
of >10 μm were present, which cannot be considered as separate whole 
particles (Figs. 3 and 4).
A slightly different picture was observed in the micropreparations of the 
tablet matrix of the drug D. Besides, the small fraction of flavonoids up to 
5 µ, a large number of solid granules in the range from 10 to 50 µ, as well 
as single huge granules of > 50 μm (Fig. 6), were observed in the most 
samples. In some micropreparations, the majority of the flavonoid fraction 
had sized up to 20 µ with a fraction of <5 µ insignificant at all (Fig. 7).
Fig. 1: Micropreparation of the tablet matrix of the drug 
“Detralex®.” A large number of granules with a size of not more 
than 5 µm. Single complex particles with sizes up to 10 µm. The 
absence of elements >10 µm ×400
Fig. 2: Micropreparation of the tablet matrix of the drug 
“Detralex.®” Flavonoid fraction granules with diameter 2 µm, 
forming a background for the all field of view (thin arrows). 
The presence of elements with diameter of about 10 µm from 
conglomerates of smaller particles (thick arrows) ×400
Fig. 3: Micropreparation of the tablet matrix of the drug 
“Detralex®.” Complex elements >10 µm (arrows). Granules with a 
size of 2 µm on all field of view ×400
Fig. 4: Micropreparation of the tablet matrix of the drug 
“Detralex®.” A large number of granules of purified flavonoid 
fraction with diameter of 2 µm. Complex granules with diameter 
about 20 µm ×600
Fig. 5: Micropreparation of the tablet matrix of the drug 
“Detralex®.” Small particles of the flavonoid fraction. The absence 
of integral elements >10 µm ×600
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The described picture confirmed by the study of micropreparations 
of the tablet matrix of the drug D with a magnification of 600 times. 
There were a large number of flavonoids in the range of 10–20 μm. 
In addition, huge particles with a size of about 50 μm and even more 
found (Figs. 8 and 9). There was a small fraction with diameter 
of about 5 µ on the all field of view on some micropreparations 
(Fig. 8).
In the study of micropreparations of the tablet matrix of drug D in the 
maximum magnification - 1000 times, it was found that the smallest 
fraction of the tablet matrix consists predominantly of particles 
with dimensions of >2 μm, which is a fundamental difference from 
“Detralex®.” In this case, most of the granules had a size of 5–10 μm 
(Figs. 10 and 11). When calculating the distribution of the particles 
of the tablet matrix, depending on the size, the following results 
were found: Fraction 1–5 μm was 12.9%, 5–10 μm - 42.5%, 10–20 
μm - 27.7%, 20–50 μm - 15.7%, and >50 μm - 1.2% (Figs. 10 and 11, 
Table 1).
The obtained results are statistically credibly different from the results 
of studying of the tablet matrix of the “Detralex®” drug and indicate 
the different degrees and quality of the process of micronization in the 
manufacturing of these agents.
In the microscopic study of the tablet matrix of the drug N, there was 
a situation similar to the test samples of the drug D. A large fraction 
of flavonoids with a size of 5–10 μm with a minor fraction of 2 μm 
and a presence of giant granules with sizes > 50 μm observed in 
micropreparations at the magnification ×400 (Figs. 12 and 13).
All mentioned above differentiate structure of the MPFF of “Detralex®” 
and the drug N.
Practically, the complete absence of the smallest fraction 
of flavonoids - 2 μm or less also confirmed in the study of 
micropreparations of the tablet matrix of the drug N in the conditions 
of greater magnification - 600 times. The vast majority of particles 
Fig. 6: Micropreparation of the tablet matrix of the drug D. Small 
fraction of flavonoids up to 5 µm on all field of view. The presence 
of integral granules 10–20 µm (thin black arrows), 20–30 µm 
(thick black arrows), and >50 µm (white arrows) ×400
Fig. 7: Micropreparation of the tablet matrix of the drug D. Most of 
the particles are in the range of 10–20 µm ×400
Fig. 8: Micropreparation of the tablet matrix of the drug D. Small 
fraction up to 5 µm. A large number of granules sized 10–20 µm. 
Single granules over 30 µm ×600
Fig. 9: Micropreparation of the tablet matrix of the drug D. The 
majority of granules are 10–20 µm in size. The presence of giant 
granules with sizes over 50 µm ×600
Table 1: Distribution of the size of the granules of the purified 
flavonoid fraction of the tablet’s matrix of “Detralex®,” drugs D 
and N depending on size
The size of the granules, μm Percentage
“Detralex®” D N
1–5 92.8±1.0 12.9±0.6* 10.0±0.6*
5–10 7.2±0.9 42.5±0.8* 68.5±1.2*
10–20 0 27.7±0.5* 13.0±0.6*
20–50 0 15.7±0.5* 5.2±0.5*
>50 0 1.2±0.2* 3.3±0.5*
*Differences are reliably with the drug “Detralex®”
507
Asian J Pharm Clin Res, Vol 11, Issue 10, 2018, 504-508
 Zupanets et al. 
following: The fraction 1–5 μm was 10.0%, 5–10 μm - 68.5%, 10–20 
μm - 13.0%, 20–50 μm - 5, 2%, and >50 μm - 3, 3% (Figs. 15 and 16, 
Table 1).
Fig. 12: Micropreparation of the tablet matrix of the drug N. 
Particles with sizes 5–10 µm. Practically, the absence of granules 
less 2 µm. Giant coherent granules >50 µm ×400
Fig. 13: Micropreparation of the tablet matrix of the drug N. A 
large number of granules sized 50 µm or more. The small fraction 
is preferably 5–10 µm in size ×400
Fig. 14: Micropreparation of the tablet matrix of the drug N. 
A large number of particles sized 5–10 μm. The presence of 
granules with sizes more than 30 μm ×600
Fig. 15: Micropreparation of the tablet matrix of the drug N. The 
vast majority of granules are 5–10 μm. Particles with diameter 
>10 μm ×1000
on these micropreparations had a size of 5–10 μm (Fig. 14). Granules 
larger 10–20 μm and 30 μm or more observed in some of them.
The results of the analysis of the distribution of the particles of the 
tablet matrix of the preparation N, depending on the size, indicate the 
Fig. 10: Micropreparation of the tablet matrix of the drug D. A cluster 
of particles with a size of 5–10 µm. Granules <2 µm are practically 
absent. The presence of integral granules with sizes >30 µm ×1000
Fig. 11: Micropreparation of the tablet matrix of the drug D. The 
vast majority of granules are 5–10 µm in size. A small number of 
particles sized <2 µm ×1000
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Fig. 16: Micropreparation of the tablet matrix of the drug N. The 
vast majority of granules are 5–10 μm. A small amount of fraction 
of flavonoids <5 μm ×1000
and 13.0% in the drug N), 20–50 µ (15.7% in the D and 5.2% in the 
N), and even >50 µ (1.2% and 3.3%, respectively);
• Microscopic analysis of the tablet matrix of the drug “Detralex®” 
showed the highest degree of micronization of the purified flavonoid 
fraction (the size of the particles of flavonoids was predominantly 
2 μm), which indicates the unconditional benefits of this agent in the 
treatment of patients with varicose disease and hemorrhoids;
• Different degrees of micronization of the purified flavonoid fraction 
in the studied test samples indicate that the drugs D and N are not 
completely pharmaceutically equivalent to the original “Detralex®” 
drug and cannot be considered as copies without further research;
• The results of the conducted research indicate that the extrapolation 
of data on efficacy and safety obtained during preclinical and clinical 
study of “Detralex®,” on medicines D and N is inadmissible.
• The appropriate in vivo comparative studies are necessary to assess 
the effect of degree and homogeneity of micronization on the 
pharmacokinetic and pharmacodynamics parameters.
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DISCUSSION
The presented results testify to the statistical differences between 
the size of the particle of the tablets matrix of drugs D and N of 
Ukrainian manufacturing from the tablet matrix of the drug “Detralex®” 
manufactured by the Laboratory Servier Industrie, France, which 
evidence about the different quality of micronization process of these 
drugs.
It is known that one of the important parameters that affect the 
solubility and absorption of drugs is the surface area of the granule 
or the fraction of the tablet matrix after the dissolution of the tablet 
itself in the human’s digestive tract. The area of the contact of drug and 
dissolvent depends on the square of granules surface, thus, the rate 
of dissolution of the drug [11]. However, not this square only, but the 
ratio volume(or mass)/surface square is important. The surface area 
of the granule with size 50 µ is larger than in a granule of 2 µ size in 
approximately 625 times (assuming that both granules are spherical). 
Hence, is it possible to assume that granules of 50 µ size are better and 
faster dissolve? No, it is impossible, because the ratio of the volume of 
particles (and hence, the mass at the same density) and the surface 
square of particles in the size of 2 µ is almost 24 times greater than that 
of particles with a size of 50 µ. Thus, reducing the size of the particles 
to be dissolved will increase this ratio and, in the end, the solubility and 
the rate of dissolution of the drug [12].
Particle size distribution, in turn, will also be more influence on the 
solubility, and therefore, on the rate and degree of absorption of the 
drug, which should lead to a more rapid and complete achievement 
of its maximum plasma concentration (Pmax). To make a reliable 
assessment of the effect of micronization on the main pharmacokinetic 
and pharmacodynamic parameters, appropriate in vivo comparative 
studies are necessary.
CONCLUSIONS
Taking into account all of the above, we can draw the following 
conclusions:
• As a result of the microscopic study of the tablet matrix of the 
test samples of the drugs “Detralex®,” D and N, a different degree 
of micronization of the purified flavonoid fraction identified. The 
content of particles of flavonoids sized 1–5 µ in “Detralex®” was 
92.8%; in the medicine D - 12.9% and in the drug N - 10.0%; in the 
size of 5–10 µ in “Detralex®” - 7.2%; in the D medicine 42.5%; and 
in the preparation N - 68.5%; larger particles were not observed in 
the “Detralex®” test specimens, in contrast to which, particles in the 
test sample of other drugs were 10–20 µ (27.7% in the D medicine 
